



# MEDICAL ASSISTANCE BULLETIN

COMMONWEALTH OF PENNSYLVANIA • DEPARTMENT OF PUBLIC WELFARE

ISSUE DATE

August 10, 2006

EFFECTIVE DATE

August 1, 2006

NUMBER

\*SEE BELOW

SUBJECT

**Measles, Mumps, Rubella and Varicella (MMRV)  
Vaccine**

BY

  
James L. Hardy, Deputy Secretary  
Office of Medical Assistance Programs

## PURPOSE:

The purpose of this bulletin is to inform providers that a new vaccine is now being supplied by the Pennsylvania Vaccines for Children (VFC) Program. Effective May 1, 2006, ProQuad®, a combined live attenuated virus vaccine indicated for simultaneous vaccination against measles, mumps, rubella and varicella (chickenpox) was added to the list of vaccines approved for the VFC Program.

## SCOPE:

This bulletin applies to all Medical Assistance (MA) enrolled providers who are authorized to administer immunizations to MA recipients. Providers rendering services to MA recipients under the MA managed care delivery system should address any coding or rate-related questions to the appropriate managed care organization (MCO).

## BACKGROUND/DISCUSSION:

On September 6, 2005, the Food and Drug Administration (FDA) licensed the combined live attenuated measles, mumps, rubella and varicella (MMRV) vaccine, ProQuad®, for use in children aged 12 months to 12 years of age. ProQuad® is the first and only vaccine in the U.S. to help protect children against measles, mumps, rubella and varicella in one injection. The American Academy of Pediatrics, the American Academy of Family Physicians, and the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommend routine vaccination against measles, mumps, rubella and varicella.

ProQuad® is approved for children at 12 months to 12 years of age. It is not indicated for the vaccination of individuals outside of this age group. ProQuad® should not be administered

\* 01-06-09 08-06-13 09-06-11 31-06-18 33-06-04

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at [www.dpw.state.pa.us/omap](http://www.dpw.state.pa.us/omap)

for the second dose of measles, mumps and rubella (MMR) except when a dose of varicella vaccine is also indicated or if no MMR is available at the time the second dose of MMR is indicated.

To access the VFC/ACIP's resolutions for MMRV and other vaccines, please log onto the CDC website at: [http://www.cdc.gov/nip/vfc/acip\\_vfc\\_resolutions.htm#res](http://www.cdc.gov/nip/vfc/acip_vfc_resolutions.htm#res).

**PROCEDURE:**

The Department of Public Welfare (Department) added ProQuad® to the PROMISe™ Drug/NDC Fee Schedule on October 10, 2005, and is currently covering this vaccine for MA-eligible children consistent with the indicated use of MMRV as licensed by the FDA and current ACIP recommendations. Although ProQuad® can now be ordered through the VFC Program for VFC-eligible adolescents from 12 months to 12 years of age, the MA Program will continue to cover the vaccine for this age group until August 31, 2006, to allow providers sufficient time to receive their vaccine from the VFC Program.

Effective September 1, 2006, the MA Program will reimburse VFC-enrolled providers for the administration of ProQuad® for MA-eligible children consistent with the indicated use of MMRV as licensed by the FDA and current ACIP recommendations. Providers may bill the Department for the administration of this vaccine using CPT code 90710. The MA fee for the administration of the vaccine is \$10.00 per administration. Providers participating in an MA MCO network must abide by payment arrangements as stated in their individual contract.